Cash, cash equivalents, and investments of $78.5 million at March 31, 2025 and cash runway anticipated to fund operations into 2028 MENLO PARK, Calif. / May 13, 2025 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the first quarter ended... Read More

EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2 study, patients had underlying severe, advanced MAC lung disease Extensive enabling NTM data provides potential path forward in M. abscessus lung disease Company focus remains centered on boron chemistry pipeline with initiation of high impact clinical programs in infectious diseases and an emerging... Read More

MENLO PARK, Calif. / Apr 30, 2025 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will participate in a fireside chat at the 2025 Citizens JMP Life Sciences Conference being held from May 7-8, 2025 in... Read More

Phase 3 topline data expected 2Q25 for epetraborole in patients with treatment-refractory MAC lung disease (TR MAC) Phase 1 first in human study of AN2-502998, under development for Chagas disease, to start mid-2025 in healthy volunteers Topline data for melioidosis observational trial expected in 2Q25; Phase 2 epetraborole study planned for 2H25 First oncology candidate(s) from boron chemistry platform on track to advance... Read More

MENLO PARK, Calif. / Mar 03, 2025 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Leerink Partners Global Healthcare Conference. Details of the event are as follows: Leerink Partners... Read More

AN2 Selects QOL-B as New Phase 3 Primary Efficacy Endpoint Goal to Accelerate Unblinding Phase 3 Data in Q2 2025 Ahead of Potential FDA Meeting MENLO PARK, Calif. / Feb 24, 2025 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced its submission of an amended... Read More

MENLO PARK, Calif. / Feb 20, 2025 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in March. Details of the events are as follows: TD Cowen 45 th Annual Health Care Conference Eric... Read More

MENLO PARK, Calif. / Jan 29, 2025 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO, will present at the Oppenheimer 35 th Annual Healthcare Life Sciences Conference. Details of the event are as follows:... Read More

MENLO PARK, Calif. / Nov 14, 2024 / Business Wire / AN2 Therapeutics, Inc . (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in December. Details of the events are as follows: 7 th Annual Evercore HealthCONx Conference,... Read More

Epetraborole-treated patients demonstrated clinical improvements in QOL-B and a post-hoc analysis of MACrO 2 with nominal statistical significance when evaluated as continuous measures First drug candidate with statistically favorable patient reported outcome (PRO)-based improvement in treatment-refractory Mycobacterium avium Complex (TR-MAC) population Company plans to meet with FDA to gain alignment on a development path... Read More

Grant from the Bill & Melinda Gates Foundation MENLO PARK, Calif. / Oct 17, 2024 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover... Read More

MENLO PARK, Calif. / Aug 28, 2024 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the H.C. Wainwright 26 th Annual Global Investment Conference. Details of the event is as follows: H.C.... Read More

MENLO PARK, Calif. / Aug 16, 2024 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025. The Company recently became aware of the rapid accumulation of a... Read More

Cash, cash equivalents, and investments of $104.5 million at June 30, 2024; cash runway anticipated to fund operations through 2027 MENLO PARK, Calif. / Aug 13, 2024 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today reported financial results for the quarter ended June 30,... Read More

EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron chemistry platform and ongoing pipeline programs Company restructuring and cost savings associated with discontinuation of the EBO-301 study expected to extend cash runway through 2027 MENLO PARK, Calif. / Aug 08, 2024 / Business Wire / AN2... Read More

Plan to report Phase 2 topline results in August 2024 from ongoing Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) Phase 3 continues for 97 patients enrolled before the voluntary enrollment pause; lifting of the Phase 3 enrollment pause to be determined after review of unblinded Phase 2 data and discussions with the FDA Cash, cash equivalents, and investments of $118.1 million at March... Read More

Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during continued analysis of incoming data; plan to discuss with FDA Cash, cash equivalents, and investments of $134.5 million at December 31, 2023 MENLO PARK, Calif. / Mar 28, 2024 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a... Read More

Enrolled patients allowed to continue on study MENLO PARK, Calif. / Feb 12, 2024 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the company’s decision to voluntarily pause Phase 3 enrollment in the seamless Phase 2/3 clinical trial (EBO-301) evaluating... Read More

MENLO PARK, Calif. / Jan 30, 2024 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the Oppenheimer 34 th Annual Healthcare Life Sciences Conference. Details of the event is as follows:... Read More

Enrollment well underway in Phase 3 part of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease On track to announce Phase 2 clinical data summer 2024 Cash and investments of $150.2 million at September 30, 2023; cash runway anticipated to fund operations through summer 2025 MENLO PARK, Calif. / Nov 09, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a... Read More

MENLO PARK, Calif. / Nov 06, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November. Stifel 2023 Healthcare Conference Eric Easom, Co-Founder, President and CEO will... Read More

License enables advancement of AN2-502998 (formerly known as AN15368), a boron-based small molecule therapeutic under development for the treatment of Chagas disease IND-enabling preclinical studies well underway in partnership with University of Georgia Chagas expert using non dilutive funding from Wellcome MENLO PARK, Calif. / Oct 18, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage... Read More

Enrollment Ongoing in Phase 3 Part of 2/3 Pivotal Trial of Epetraborole in Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease MENLO PARK, Calif. / Oct 11, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced two oral presentations and... Read More

Grant from Bill & Melinda Gates Foundation MENLO PARK, Calif. / Sep 26, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that it has received a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small... Read More

Company announces Phase 2 part of the EBO-301 trial is now fully enrolled with 80 patients; Topline Phase 2 trial results expected in summer 2024 Over 100 sites across four countries (U.S., Japan, S. Korea & Australia) as epetraborole enters Phase 3 portion of EBO-301; expected to enroll ~230 patients MENLO PARK, Calif. / Sep 13, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical... Read More

MENLO PARK, Calif. / Aug 15, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of an underwritten offering of 7,777,778 shares of its common stock. The shares of common stock are being sold at a price of $9.00 per share, a premium from... Read More

Sufficient patients in screening expected to complete enrollment in Phase 2 portion of pivotal Phase 2/3 study of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease Expected initiation of Phase 3 portion of pivotal Phase 2/3 study in September MENLO PARK, Calif. / Aug 10, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on... Read More

MENLO PARK, Calif. / May 25, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO, will present at the Jefferies Healthcare Conference. Details of the event are as follows: Jefferies Healthcare Conference,... Read More

Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease MENLO PARK, Calif. / May 11, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the... Read More

MENLO PARK, Calif. / May 01, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO, will present at the JMP Securities Life Sciences Conference. Details of the event is as follows: JMP Securities Life... Read More

Approaching 60 clinical sites participating in pivotal Phase 2/3 trial of epetraborole in treatment-refractory Mycobacterium avium complex (MAC) lung disease to date Opened up sites in three additional countries -- Japan, South Korea, and Australia in addition to the U.S.; Japan has some of the highest rates of MAC lung disease in the world Activities underway to advance development of epetraborole for acute systemic... Read More

MENLO PARK, Calif. / Feb 28, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in March. Details of the events are as follows: Cowen 43 rd Annual Health Care Conference,... Read More

MENLO PARK, Calif. / Jan 31, 2023 / Business Wire / AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO will present at the SVB Securities Global Biopharma Conference. Details of the event is as follows: SVB Securities Global... Read More